Corporate Finance

In a major strategic shift, Matthews Asia's founders are buying back control, reinforcing the firm's independent identity and hiring a top China expert.

The uranium giant posted a massive jump in 2025 earnings, fueled by strategic investments and a global rush for clean, secure energy. Here's what's next.

Rithm Property Trust reports positive GAAP income but negative cash flow, raising questions about its dividend sustainability amid a major strategic pivot.

The pipeline giant's record $20B EBITDA is fueled by traditional energy, while it aggressively expands into renewables to power the digital economy.

Riding a wave of demand from data centers and LNG, TC Energy reports record flows, strong 2025 earnings, and its 26th straight dividend increase.

Helion's Polaris prototype achieves a private industry first with 150M°C plasma and D-T fusion, accelerating its plan to power Microsoft by 2028.

Magna beat Q4 expectations and raised its dividend, but a $591M tech impairment and looming Ford recall costs paint a complex picture for the auto giant.

Finnish medtech firm Bioretec reports staggering 2025 losses but bets its future on breakthrough implant technology and a complete strategic overhaul.

The aquaculture tech giant posts 41% revenue growth, driven by a 94% surge in its land-based division, signaling a major industry shift.

The global lighting leader will repurchase 725,000 shares, a strategic move to cover employee incentives, manage dilution, and signal financial health.

The wealth management giant reports record earnings and massive client inflows, signaling confidence and a focus on shareholder returns in a competitive market.

With strong financials and a focus on tech, Allegion's CEO will outline the security giant's long-term strategy for a digitally connected world.

With massive data center orders but cautious guidance, the industrial giant's upcoming conference talks are a key test of investor confidence.

Twilio reports a landmark year of GAAP profitability and robust growth, signaling a strategic pivot to AI as it guides for a billion in 2026 cash flow.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

The SaaS firm posts strong net income and recurring revenue growth from its B2B platform, offsetting a decline in its transactional business.

Brazil's fintech leader reports a record R$5.2B adjusted net income for 2025, outlining a strategy that pairs AI with human advisors to win the market.

The Oreo maker's latest dividend declaration reinforces its reliability for investors, even as it navigates cost pressures and shifting consumer habits.

As Yellowknife faces a dire housing shortage and rising homelessness, all eyes are on a major federal-territorial announcement. Will it be a lifeline?